Resource Summary Report

Generated by NIF on Sep 17, 2026

HCC1428

RRID:CVCL_1252
Type: Cell Line

Proper Citation

RRID:CVCL_1252

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1252

Proper Citation: RRID:CVCL_1252

Description: Cell line HCC1428 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: PMID:9288768, PMID:9833771, PMID:11314036, PMID:17157791, PMID:19582160, PMID:20070913, PMID:20215515, PMID:20679594, PMID:22460905, PMID:22585861, PMID:23151021, PMID:24094812, PMID:24162158, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28287265, PMID:30894373, PMID:31068700, PMID:35839778

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1428

Synonyms: HCC-1428, Hamon Cancer Center 1428

Cross References: CLO:CLO_0003637, EFO:EFO_0001171, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2327, BioGRID_ORCS_Cell_line:664, BioSample:SAMN03472560,

BioSample:SAMN10988527, cancercelllines:CVCL_1252, Cell_Model_Passport:SIDM00881, CLS:305782, Cosmic:904364, Cosmic:1460233, Cosmic:1603202, Cosmic:1995423, Cosmic:2165021, Cosmic:2750521, Cosmic-CLP:1290905, DepMap:ACH-000352, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1290905, GEO:GSM274666, GEO:GSM344373, GEO:GSM344423, GEO:GSM350510, GEO:GSM827277, GEO:GSM887039, GEO:GSM888109, GEO:GSM1008898, GEO:GSM1053693, GEO:GSM1172865, GEO:GSM1172958, GEO:GSM1214570, GEO:GSM1613822, GEO:GSM1669845, IARC_TP53:22818, IARC_TP53:30203, KCLB:9S1428, LiGeA:CCLE_644, LINCS_HMS:50208, LINCS_LDP:LCL-1467, PharmacoDB:HCC1428_475_2019, PRIDE:PXD005390, PRIDE:PXD030304, Progenetix:CVCL_1252, SLKBase:3517, Wikidata:Q54881570

ID: CVCL_1252

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260913T003950+0000

Ratings and Alerts

No rating or validation information has been found for HCC1428.

No alerts have been found for HCC1428.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 132 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Johnson Thomas AL, et al. (2026) Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer. Molecular oncology.

Sottnik JL, et al. (2026) Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer research, 86(7), 1605.

Han S, et al. (2026) Celecoxib potentiates ribociclib-induced apoptosis and anti-tumor activity by co-targeting COX-2/NF-?B and PI3K/AKT/mTOR pathways in hormone receptor-positive/HER2-negative breast cancer. Apoptosis : an international journal on programmed cell death, 31(5).

Sottnik JL, et al. (2026) Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling. bioRxiv : the preprint server for biology.

Duan L, et al. (2025) Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells. Molecular cancer therapeutics, 24(7), 1020.

Suresh S, et al. (2025) PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. Scientific reports, 15(1), 36766.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine, 6(11), 102446.

Williams J, et al. (2025) Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis. Nature communications, 16(1), 7438.

Bhagwat SV, et al. (2025) Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. Cancer research, 85(4), 777.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Anagho HA, et al. (2024) ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines. Cell reports, 43(7), 114433.

Sobsey CA, et al. (2024) mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications, 4(8), 2058.

Albrecht J, et al. (2024) Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance. Molecular oncology.

Xu F, et al. (2023) C1ql4 regulates breast cancer cell stemness and epithelial-mesenchymal transition through PI3K/AKT/NF-?B signaling pathway. Frontiers in oncology, 13, 1192482.

Kjølle S, et al. (2023) Hypoxia induced responses are reflected in the stromal proteome of breast cancer. Nature communications, 14(1), 3724.

Granadillo Rodríguez M, et al. (2023) Similar deamination activities but different phenotypic outcomes induced by APOBEC3 enzymes in breast epithelial cells. Frontiers in genome editing, 5, 1196697.

Cipolletti M, et al. (2023) A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ER? expressing primary and metastatic invasive ductal carcinoma. Frontiers in endocrinology, 14, 1129162.

Cervia LD, et al. (2023) A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. Cancer discovery, 13(3), 766.

Li B, et al. (2023) Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer. Cancer research, 83(17), 2924.